158 related articles for article (PubMed ID: 32425509)
1. BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT
Patti F; Martínez Ginés ML; Norenberg C; Duarte Caron F
Patient Prefer Adherence; 2020; 14():771-779. PubMed ID: 32425509
[TBL] [Abstract][Full Text] [Related]
2. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
Kleiter I; Lang M; Jeske J; Norenberg C; Stollfuß B; Schürks M
BMC Neurol; 2017 Sep; 17(1):174. PubMed ID: 28877664
[TBL] [Abstract][Full Text] [Related]
3. Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.
Barone DA; Singer BA; Merkov L; Rametta M; Suarez G
Neurol Ther; 2016 Dec; 5(2):155-167. PubMed ID: 27277705
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT
Köhler W; Bayer-Gersmann K; Neußer T; Schürks M; Ziemssen T
Front Neurol; 2021; 12():643126. PubMed ID: 33716945
[No Abstract] [Full Text] [Related]
5. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Ziemssen T; Sylvester L; Rametta M; Ross AP
Neurol Ther; 2015 Dec; 4(2):125-36. PubMed ID: 26662362
[TBL] [Abstract][Full Text] [Related]
6. Real-World Assessment of Interferon-β-1b and Interferon-β-1a Adherence Before and After the Introduction of the BETACONNECT
Butler O; Heeg S; Holl K; Frenz AK; Wicklein EM; Rametta M; Yeo S
Drugs Real World Outcomes; 2021 Sep; 8(3):359-367. PubMed ID: 33928518
[TBL] [Abstract][Full Text] [Related]
7. A Prospective, Observational, Multicenter Study Assessing Adherence to Interferon Beta-1b Therapy and Patient Satisfaction Using the BETACONNECT Auto-Injector.
Farej R; Rametta M; La Rose A; Quillen A; McLeod K
Neurol Ther; 2022 Mar; 11(1):373-384. PubMed ID: 35064907
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp).
Limmroth V; Hechenbichler K; Müller C; Schürks M
J Med Internet Res; 2019 Jul; 21(7):e14373. PubMed ID: 31359863
[TBL] [Abstract][Full Text] [Related]
9. Autoinjector preference among patients with multiple sclerosis: results from a national survey.
Limmroth V; Reischl J; Mann B; Morosov X; Kokoschka A; Weller I; Schreiner T
Patient Prefer Adherence; 2017; 11():1325-1334. PubMed ID: 28831243
[TBL] [Abstract][Full Text] [Related]
10. Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β-1b: Observational Study.
Limmroth V; Bayer-Gersmann K; Mueller C; Schürks M
JMIR Form Res; 2022 Mar; 6(3):e31972. PubMed ID: 35285806
[TBL] [Abstract][Full Text] [Related]
11. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Boeru G; Milanov I; De Robertis F; Kozubski W; Lang M; Rojas-Farreras S; Tomlinson M
Med Devices (Auckl); 2013; 6():175-84. PubMed ID: 24255602
[TBL] [Abstract][Full Text] [Related]
12. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
Hoffmann FA; Trenova A; Llaneza MA; Fischer J; Lus G; von Bredow D; Lara N; Lam E; Van Hoef M; Bakshi R
BMC Neurol; 2017 Aug; 17(1):156. PubMed ID: 28793876
[TBL] [Abstract][Full Text] [Related]
13. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
14. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
Singer B; Wray S; Miller T; Cascione M; Gupta A; Pardo G; Watsky E; Hayward B; Mercer B; Dangond F
Mult Scler Relat Disord; 2012 Apr; 1(2):87-94. PubMed ID: 25876936
[TBL] [Abstract][Full Text] [Related]
15. Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b.
Weller I; Saake A; Schreiner T; Vogelreuter J; Petroff N
Patient Prefer Adherence; 2015; 9():951-9. PubMed ID: 26185425
[TBL] [Abstract][Full Text] [Related]
16. Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study.
Steinberg SC; Faris RJ; Chang CF; Chan A; Tankersley MA
Clin Drug Investig; 2010; 30(2):89-100. PubMed ID: 20067327
[TBL] [Abstract][Full Text] [Related]
17. Assessment of adherence to, and persistence with, an electromechanical autoinjector for subcutaneous interferon beta-1a injections for multiple sclerosis treatment over 3 years.
Piras F; Arnaud L; Henninger E; Keiser M; Seitzinger A; Jack D; Le Masne Q
Expert Opin Drug Deliv; 2023 Jun; 20(6):863-870. PubMed ID: 37273189
[TBL] [Abstract][Full Text] [Related]
18. Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort
Thakur K; Manuel L; Tomlinson M
Pragmat Obs Res; 2013; 4():19-26. PubMed ID: 27774021
[TBL] [Abstract][Full Text] [Related]
19. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.
Devonshire V; Arbizu T; Borre B; Lang M; Lugaresi A; Singer B; Verdun di Cantogno E; Cornelisse P
BMC Neurol; 2010 Apr; 10():28. PubMed ID: 20433746
[TBL] [Abstract][Full Text] [Related]
20. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices].
Brochet B; Lemaire G; Beddiaf A;
Rev Neurol (Paris); 2006 Jun; 162(6-7):735-40. PubMed ID: 16840982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
